Bone marrow transplantation for acute lymphoblastic leukemia (ALL)

Area of Science:

• Hematology
• Oncology
• Transplantation

Background:

• Childhood acute lymphoblastic leukemia (ALL) treatment has advanced significantly, but adult ALL outcomes remain less impressive.
• Age is the most critical prognostic factor in ALL, with adults experiencing more frequent relapses and fewer cures.
• Biologic differences in disease behavior between pediatric and adult ALL contribute to outcome disparities.

Purpose of the Study:

• To evaluate the efficacy of bone marrow transplantation (BMT) in adult patients with ALL, particularly in first complete remission.
• To compare outcomes of allogeneic and autologous BMT in adult ALL.
• To discuss the challenges and biases in comparing BMT with conventional therapies for adult ALL.

Main Methods:

• Review of studies on bone marrow transplantation for adult ALL.
• Comparison of outcomes between allogeneic and autologous BMT.
• Analysis of factors influencing survival, including graft-versus-host disease, opportunistic infections, and graft-versus-leukemia effect.

Main Results:

• Approximately 40-50% of adult ALL patients in first complete remission achieve long-term disease-free survival after BMT (allogeneic or autologous).
• Autologous BMT shows higher relapse rates compared to allogeneic BMT.
• Allogeneic BMT is associated with increased risks of graft-versus-host disease and opportunistic infections.

Conclusions:

• BMT may offer improved disease-free survival for adult ALL compared to conventional treatments, but patient selection is crucial.
• Neither allogeneic nor autologous BMT appears definitively superior, with trade-offs in relapse rates and treatment-related toxicity.
• Well-designed, prospective, randomized trials are necessary to definitively compare BMT with conventional therapy for adult ALL.